Pitney Pharmaceuticals Pty Limited

Angiodynamics, Inc.

Resect Medical, Inc.

S.d.m.h. Pty. Ltd.

Newsouth Innovations Pty Limited

Mrc Holdings Pty Limited

David Lawson Morris

Steven A Daniel

Roger Aston

Mohammad Hossein Pourgholami

Daniel J Balbierz

Koji Tanaka

Nobuharu Andoh

Tomokazu Hino

Osamu Sanpei

Tetsuo Toga

Kee S Lee

Steve A Daniel

Javed Akhter

Krishna Pillai

The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

Treatment of diseases involving mucin

The present invention relates to synergistic compositions comprising bromelain, or a proteolytic fraction thereof, and cysteamine or a metabolite, pharmaceutically acceptable salt, solvate or prodrug thereof The invention also relates to methods and uses of such compositions for the treatment of diseases involving mucin.

Compositions and methods for the treatment of diseases involving mucin

The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein Ris a hydrogen atom, an alkyl group and the like, R, R, and Rare the same or different and each is a hydrogen atom, an alkyl group and the like, Rand Rare the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Aris a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, or &#x2014;N(R)&#x2014; wherein Ris a hydrogen atom, a (C-C)alkyl group and the like, or a pharmacologically acceptable salt thereof. 

Anti-cancer agent comprising aminoacetonitrile compound as active ingredient

The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein Ris a hydrogen atom, an alkyl group and the like, R, R, and Rare the same or different and each is a hydrogen atom, an alkyl group and the like, Rand Rare the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Aris a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, or &#x2014;N(R)&#x2014; wherein Ris a hydrogen atom, a (C-C) alkyl group and the like, or a pharmacologically acceptable salt thereof.

Anticancer agent comprising aminoacetonitrile compound as active ingredient

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Compounds for the treatment of mTOR pathway related diseases

The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein Ris a hydrogen atom, an alkyl group and the like, R, R, and Rare the same or different and each is a hydrogen atom, an alkyl group and the like, Rand Rare the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Aris a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, or &#x2014;N(R)&#x2014; wherein Ris a hydrogen atom, a (C-C)alkyl group and the like, or a pharmacologically acceptable salt thereof. 

The present invention relates to pharmaceutical combinations comprising aminoacetonitrile derivatives and anticancer compounds. Further, the present invention relates to these pharmaceutical combinations for use in the treatment of cancer.

Pharmaceutical combinations for the treatment of cancer

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of cancer.

Kinase inhibitors for the treatment of cancer

A tissue ablation system including numerous components and methods is described herein for encircling target tissue and generating tissue ablation volumes in various biological tissues. The biological tissue includes tissue of a variety of organs of the human body including the liver, spleen, kidney, lung, breast and other organs, but is not so limited. The tissue ablation device comprises an energy source and at least one trocar coupled to the energy source, the trocar having a body, a proximal end, and a distal end. The trocar carries an electrode array that comprises a plurality of electrodes, each electrode of the plurality of electrodes is configured to extend from the trocar when moved from a retracted state to a deployed state, and to have at least one radius of curvature in the deployed state so that the electrode array forms a series of shaped electrodes in the deployed state.

Devices and methods for thermal ablation of biological tissue using geometric ablation patterns

Energy delivery systems and methods are provided for use in biological tissue. The energy delivery system includes an energy source and an electrode array. The electrode array includes bipolar electrodes positioned so a first spacing between a pair of adjacent electrodes is different relative to a second spacing between at least one other pair of adjacent electrodes. The electrode array and the energy source are coupled and configured to generate uniform energy density in target tissue according to impedance of the target tissue.

Thermal hemostasis and/or coagulation of tissue

The present invention provides methods for inhibiting VEGF production or secretion in a subject comprising administering to the subject an effective amount of a compound of Formula I. The invention also provides methods for the treatment or prevention of conditions associated with abnormal levels of VEGF production or secretion.

VEGF inhibition

A tissue ablation device and method for tissue ablation are described. The tissue ablation device comprises an energy source and an introducer coupled to the energy source, the introducer having a body, a proximal end, and a distal end. The introducer carries an electrode array that comprises a plurality of electrodes, each electrode of the plurality of electrodes is configured to extend from the body of the introducer when moved from a retracted state to a deployed state. The electrode array is designed to encircle a portion of a target tissue when the electrodes are extended into the deployed state and to form a relatively spherical shaped ablation pattern in a tissue volume surrounding the target tissue when energized by the energy source.

Device and method for thermal ablation of biological tissue using spherical ablation patterns

The present invention provides methods for the treatment of tumors, comprising administration of an effective amount of at least one taxoid and an effective amount of at least one benzimidazol carbamate compound of formula (I). The invention also provides a method for the treatment of tumors insensitive to one or more anti-mitotic drugs, the method comprising administering a effective amount of at least one benzimidazole carbamate compound of formula (I). Also provide are compositions for carrying out methods of the invention.

Treatment for cancer

A method of controlling ablation volume depth includes providing a treatment apparatus. The apparatus comprises a housing having a proximal and distal end including a tissue contacting surface. The housing defines an interior with an energy delivery device positionable in the interior. The energy delivery device includes at least one electrode with a tissue penetrating distal end and is configured to be advanced from the interior into a target tissue site to define an ablation volume. An advancement device is coupled to the energy delivery device and is configured to advance the at least one electrode. The at least one electrode is advanced to a selected deployment depth beneath a tissue surface while avoiding a critical structure. Energy is delivered from the energy delivery device. An ablation volume is created at a controlled depth below the tissue surface responsive to the deployment depth while minimizing injury to the critical structure.

Growing community of inventors

Lugarno, Australia

David Lawson Morris